Compagnie Lombard Odier SCmA Has $8.53 Million Stock Position in Medtronic PLC $MDT

Key Points

• Compagnie Lombard Odier SCmA reduced its stake in Medtronic PLC by 4.7%, now holding 97,832 shares valued at approximately $8.53 million.
• Medtronic's recent quarterly earnings report showed a revenue of $8.58 billion, exceeding estimates and reflecting a 7.7% year-over-year growth with earnings per share of $1.26.
• The company has declared a quarterly dividend of $0.71 per share, resulting in an annualized dividend yield of 3.0%.

Compagnie Lombard Odier SCmA cut its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 4.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,832 shares of the medical technology company's stock after selling 4,859 shares during the period. Compagnie Lombard Odier SCmA's holdings in Medtronic were worth $8,528,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. 1248 Management LLC acquired a new position in shares of Medtronic in the 1st quarter valued at approximately $26,000. Burkett Financial Services LLC lifted its stake in Medtronic by 185.0% in the first quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock valued at $26,000 after buying an additional 185 shares in the last quarter. Columbia River Financial Group LLC acquired a new position in shares of Medtronic in the first quarter valued at approximately $28,000. Twin Tree Management LP bought a new stake in shares of Medtronic during the first quarter worth $29,000. Finally, Activest Wealth Management increased its position in shares of Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock worth $30,000 after acquiring an additional 322 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on MDT shares. Wolfe Research upgraded Medtronic from an "underperform" rating to a "peer perform" rating in a report on Monday, June 30th. Leerink Partners assumed coverage on Medtronic in a report on Monday, June 16th. They set an "outperform" rating and a $110.00 price objective for the company. Citigroup boosted their target price on Medtronic from $99.00 to $101.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. UBS Group upped their price target on Medtronic from $94.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 20th. Finally, Evercore ISI lifted their price objective on shares of Medtronic from $103.00 to $106.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $102.27.

Insider Activity

In other news, Director William R. Jellison acquired 2,500 shares of Medtronic stock in a transaction on Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company's stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.26% of the company's stock.

Medtronic Stock Down 0.4%

Medtronic stock opened at $94.69 on Tuesday. The firm's fifty day moving average is $92.15 and its 200 day moving average is $88.29. The company has a market capitalization of $121.45 billion, a PE ratio of 26.08, a PEG ratio of 2.50 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $96.25.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the company posted $1.23 earnings per share. The business's revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic's dividend payout ratio is presently 78.24%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.